[Federal Register Volume 66, Number 152 (Tuesday, August 7, 2001)]
[Notices]
[Pages 41244-41245]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 01-19656]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[60 Day-01-55]


Proposed Data Collections Submitted for Public Comment and 
Recommendations

    In compliance with the requirement of section 3506(c)(2)(A) of the 
Paperwork Reduction Act of 1995 for opportunity for public comment on 
proposed data collection projects, the Centers for Disease Control and 
Prevention (CDC) will publish periodic summaries of proposed projects. 
To request more information on the proposed projects or to obtain a 
copy of the data collection plans and instruments, call the CDC Reports 
Clearance Officer on (404) 639-7090.
    Comments are invited on: (a) Whether the proposed collection of 
information is necessary for the proper performance of the functions of 
the agency, including whether the information shall have practical 
utility; (b) the accuracy of the agency's estimate of the burden of the 
proposed collection of information; (c) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (d) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques or other 
forms of information technology. Send comments to Seleda Perryman, CDC 
Assistant Reports Clearance Officer, 1600 Clifton Road, MS-D24, 
Atlanta, GA 30333. Written comments should be received within 60 days 
of this notice.
    Proposed Project: Evaluating the Impact of Lymphedema and a 
Lymphedema Management Intervention for Women with Lymphatic Filariasis: 
Understanding Issues Related to Quality of Life--New--National Center 
for Infectious Diseases (NCID), Centers for Disease Control and 
Prevention (CDC). Lymphatic filariasis, a mosquito-transmitted 
parasitic disease affecting over 120 million people, is the second 
leading cause of permanent disability worldwide. Globally, lymphatic 
filariasis causes debilitating genital disease in an estimated 25 
million men and lymphedema or elephantiasis of the leg in 15 million 
people, mostly women in poverty stricken countries. The World Health 
Organization (WHO) recently identified community management of chronic 
lymphedema as one of the top twenty lymphatic filariasis research 
priorities. Recent advances in the management of chronic lymphedema 
include a prescribed hygiene and wound care intervention. This 
intervention has shown promising results in preventing bacterial 
infections thus reducing acute attacks, and anecdotally improving 
overall quality of life, alleviating pain and preventing further 
suffering.
    This pilot study will provide a micro-level perspective of women's 
own experiences of living with lymphedema and others responses to it, 
illuminating the nature of the disease, the vulnerability of those 
disabled by the disease, and the impact of an intervention to influence 
the consequences of having the disease. This study will provide a 
better understanding, through a combination of qualitative and 
quantitative methods, the influence of lymphadema as well as the 
efficacy of a lymphedema management intervention in reducing episodes 
of bacterial infections and improving quality of life in women with 
lymphedema in two developing countries.
    Women will be queried through in-depth interviews, focus groups, 
and questionnaire surveys as to the influence of lymphadema on their 
lives. Quality of life domains that will be explored include physical 
health, psychological health, social relationships, economic 
productivity, spiritual health, stigma, and environment. 
Recommendations will be derived from this study for the global 
community of lymphatic filariasis researchers in developing countries 
initiating national and local programs for the management of chronic 
lymphedema. There are no costs to respondents.

----------------------------------------------------------------------------------------------------------------
                                                                     Number of    Average burden
               Women  respondents                    Number of    responses  per   per  response   Total burden
                                                    respondents     respondents     (in hours)      (in hours)
----------------------------------------------------------------------------------------------------------------
Qualitative interviews in site A and site B.....              50               1           30/60              25

[[Page 41245]]

 
Quantitative Survey in site A and site B........             200               1               1             200
                                                 ---------------------------------------------------------------
    Total.......................................             250                                             225
----------------------------------------------------------------------------------------------------------------


    Dated: July 30, 2001.
Nancy Cheal,
Acting Associate Director for Policy, Planning and Evaluation, Centers 
for Disease Control and Prevention.
[FR Doc. 01-19656 Filed 8-6-01; 8:45 am]
BILLING CODE 4163-18-P